Items where Author is "Fluck, Michael"

Article

Becker, Joergen C. and Ugurel, Selma and Leiter, Ulrike and Meier, Friedegund and Gutzmer, Ralf and Haferkamp, Sebastian and Zimmer, Lisa and Livingstone, Elisabeth and Eigentler, Thomas K. and Hauschild, Axel and Kiecker, Felix and Hassel, Jessica C. and Mohr, Peter and Fluck, Michael and Thomas, Ioannis and Garzarolli, Marlene and Grimmelmann, Imke and Drexler, Konstantin and Spillner, Alexandra N. and Eckhardt, Sebastian and Schadendorf, Dirk (2023) Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial. LANCET, 402 (10404). pp. 798-808. ISSN 0140-6736, 1474-547X

Zimmer, Lisa and Livingstone, Elisabeth and Hassel, Jessica C. and Fluck, Michael and Eigentler, Thomas and Loquai, Carmen and Haferkamp, Sebastian and Gutzmer, Ralf and Meier, Friedegund and Mohr, Peter and Hauschild, Axel and Schilling, Bastian and Menzer, Christian and Kieker, Felix and Dippel, Edgar and Rosch, Alexander and Simon, Jan-Christoph and Conrad, Beate and Korner, Silvia and Windemuth-Kieselbach, Christine and Schwarz, Leonora and Garbe, Claus and Becker, Juergen C. and Schadendorf, Dirk (2022) Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial. LANCET, 400 (10358). pp. 1117-1129. ISSN 0140-6736, 1474-547X

Zimmer, Lisa and Livingstone, Elisabeth and Hassel, Jessica C. and Fluck, Michael and Eigentler, Thomas and Loquai, Carmen and Haferkamp, Sebastian and Gutzmer, Ralf and Meier, Friedegund and Mohr, Peter and Hauschild, Axel and Schilling, Bastian and Menzer, Christian and Kieker, Felix and Dippel, Edgar and Roesch, Alexander and Simon, Jan-Christoph and Conrad, Beate and Koerner, Silvia and Windemuth-Kieselbach, Christine and Schwarz, Leonora and Garbe, Claus and Becker, Juergen C. and Schadendorf, Dirk (2020) Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. LANCET, 395 (10236). pp. 1558-1568. ISSN 0140-6736, 1474-547X

Conference or Workshop Item

Schadendorf, Dirk and Richtig, Erika and Loquai, Carmen and Forschner, Andrea and Gutzmer, Ralf and Haferkamp, Sebastian and Utikal, Jochen and Hassel, Jessica Cecile and Meier, Friedegund and Debus, Dirk and Fluck, Michael and Goeppner, Daniela and Kehrer, Helmut and Dummer, Reinhard and von Moos, Roger and Thompson, Jan and Gengenbacher, Laura and Michielin, Olivier and Hoeller, Christoph (2022) Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma: an ongoing multi-centric, multi-national, prospective, longitudinal, non-interventional study - BERING-Melanoma. In: 35. Deutscher Krebskongress, Krebsmedizin: Schnittstellen zwischen Innovation und Versorgung, 13.–16. November 2022, Berlin.

Richtig, Erika and Gutzmer, Ralf and Loquai, Carmen and Utikal, Jochen and Hoeller, Christoph and Stadler, Rudolf and Forschner, Andrea and Hassel, Jessica Cecile and Goeppner, Daniela and Fluck, Michael and Haferkamp, Sebastian and Kaatz, Martin and Welslau, Manfred and Dummer, Reinhard and Von Moos, Roger Anton Fredy and Schmidt, Andrea and Milde, Laura and Michielin, Olivier and Schadendorf, Dirk (2021) Encorafenib plus Binimetinib in patients with locally advanced, unresectable or metastatic BRAF(V600)-mutant melanoma: First data of the multicenter, multinational, prospective, non-interventional longitudinal study BERING(MELANOMA). In: 2021 ASCO Annual Meeting, 4. Juni - 8. Juni 2021, Online.